blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP4103563

EP4103563 - HETEROCYCLIC GLP-1 AGONISTS [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  18.11.2022
Database last updated on 19.07.2024
FormerThe international publication has been made
Status updated on  20.08.2021
Most recent event   Tooltip02.02.2024Supplementary search reportpublished on 06.03.2024  [2024/10]
02.02.2024Change - classificationpublished on 06.03.2024  [2024/10]
02.02.2024Change - classificationpublished on 06.03.2024  [2024/10]
Applicant(s)For all designated states
Gasherbrum Bio, Inc.
2145 Clement St.
San Francisco, California 94121 / US
[2022/51]
Inventor(s)01 / MENG, Qinghua
5th Floor No. 1 South Bldg. 4560 JinKe Rd
Zhangjiang Hi-Tech Park
Shanghai 201210 / CN
02 / LIN, Xichen
5th Floor No. 1 South Bldg. 4560 JinKe Rd
Zhangjiang Hi-Tech Park
Shanghai 201210 / CN
03 / JENNINGS, Andrew
2145 Clement St.
San Francisco, California 94121 / US
 [2022/51]
Representative(s)Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
[2022/51]
Application number, filing date21753402.309.02.2021
[2022/51]
WO2021CN76260
Priority number, dateWO2020CN7510313.02.2020         Original published format: PCT/CN2020/075103
WO2020CN7510513.02.2020         Original published format: PCT/CN2020/075105
[2022/51]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2021160127
Date:19.08.2021
Language:EN
[2021/33]
Type: A1 Application with search report 
No.:EP4103563
Date:21.12.2022
Language:EN
The application published by WIPO in one of the EPO official languages on 19.08.2021 takes the place of the publication of the European patent application.
[2022/51]
Search report(s)International search report - published on:CN19.08.2021
(Supplementary) European search report - dispatched on:EP01.02.2024
ClassificationIPC:C07D405/14, C07D405/04, C07D401/04, A61K31/497, A61K31/4427, A61P3/10, A61P3/00
[2022/51]
CPC:
C07D471/04 (EP,US); A61K31/444 (US); A61K31/137 (US);
A61K31/155 (US); A61K31/423 (US); A61K31/497 (US);
A61K31/506 (US); A61K38/1709 (US); A61K38/26 (US);
A61K38/28 (US); A61K39/3955 (US); A61P3/00 (EP);
A61P3/10 (EP); C07D405/14 (EP) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/51]
TitleGerman:HETEROCYCLISCHE GLP-1-AGONISTEN[2022/51]
English:HETEROCYCLIC GLP-1 AGONISTS[2022/51]
French:AGONISTES HÉTÉROCYCLIQUES DE GLP-1[2022/51]
Entry into regional phase01.09.2022National basic fee paid 
01.09.2022Search fee paid 
01.09.2022Designation fee(s) paid 
01.09.2022Examination fee paid 
Examination procedure01.09.2022Examination requested  [2022/51]
31.03.2023Amendment by applicant (claims and/or description)
Fees paidRenewal fee
14.12.2022Renewal fee patent year 03
14.12.2023Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[E]WO2021112538  (HYUNDAI PHARM CO LTD [KR]) [E] 1,5-23,25-32* the whole document; in particular the claims and examples; example 110 p.30; cAMP activity data p.82f *
International search[A]CN110325530  (PFIZER) [A] 1-203 * see claims 1, 24; description, examples *;
 [A]WO2019239371  (PFIZER [US]) [A] 1-203* see claims 1, 20; description, examples *;
 [PX]WO2020103815  (QILU REGOR THERAPEUTICS INC [CN]) [PX] 1, 3-40, 57-125, 166-203 * see claims 1, 38-39; description, example 6 *;
 [PX]WO2020207474  (QILU REGOR THERAPEUTICS INC [CN]) [PX] 1-203 * see claims 1, 21-22; description, example 4 *;
 [PX]WO2020263695  (LILLY CO ELI [US]) [PX] 2-30, 41-93, 102, 125-203 * see claims 1, 8; description, examples 3-6 *;
 [PX]WO2021018023  (THE TITAN LEADING MED TECH INC [CN]) [PX] 1, 3-40, 57-125, 166-203 * see claims 1, 10; detailed description *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.